Financial Performance - For the three months ended March 31, 2020, total operating expenses were $4,114,933, a decrease of 53.5% compared to $8,841,293 for the same period in 2019[85]. - The net and comprehensive loss for the three months ended March 31, 2020, was $3,918,663, compared to a loss of $8,492,825 for the same period in 2019, indicating a 53.8% improvement[85]. - Net loss for Q1 2020 was $3.9 million, a decrease from a net loss of $8.5 million in Q1 2019[91]. - Net cash used in operating activities for Q1 2020 was $3.9 million, compared to $9.1 million in Q1 2019[94]. - Total other income for Q1 2020 was $196,270, a decrease from $348,468 in Q1 2019[88]. Operating Expenses - Research and development expenses for the three months ended March 31, 2020, were $1,829,042, down from $5,586,251 in the prior year, reflecting a reduction of 67.2%[85]. - General and administrative expenses decreased to $2,285,891 for the three months ended March 31, 2020, compared to $3,255,042 for the same period in 2019, a reduction of 29.8%[85]. - Research and development expenses for Q1 2020 decreased by approximately $3.8 million or 67.3% compared to Q1 2019[87]. - General and administrative expenses for Q1 2020 decreased by approximately $1.0 million or 29.8% compared to Q1 2019[88]. Cash Position - As of March 31, 2020, the company had cash reserves of $34.6 million as of March 31, 2020, which are expected to fund operations through at least the second quarter of 2021[78]. - Cash and cash equivalents as of March 31, 2020, were $34.6 million, with an accumulated deficit of $146.2 million[91]. - The company anticipates that existing cash and cash equivalents will support operations through at least Q2 2021[91]. Strategic Plans - The company plans to initiate a Phase 2 clinical trial for its glaucoma program in Q3 2020, with results expected in Q1 2021, subject to potential delays due to COVID-19[74]. - The company is developing ARP-1536, a humanized monoclonal antibody for diabetic vascular complications, and a bispecific antibody targeting both VEGF and VE-PTP[77]. - The company continues to explore strategic alternatives, including potential acquisitions or mergers, to maximize stockholder value[91]. Clinical Trials - In the TIME-2b trial, subcutaneous AKB-9778 showed a 21% reduction in Urine Albumin-Creatinine Ratio (UACR) from baseline, indicating potential benefits in diabetic kidney disease[75]. Other Financial Information - The company recorded a severance expense of $1.9 million in 2019 due to a realignment plan and leadership changes[78]. - There were no investing cash flows in Q1 2020, and no financing cash flows during the same period[95][96]. - No shares of common stock had been sold under the Controlled Equity Offering Sales Agreement as of March 31, 2020[91].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38560 Aerpio Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware (State or other jurisdiction of in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-38560 Aerpio Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaw ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-38560 Aerpio Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------|-- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38560 | --- | --- | |---------------------------------------------------------------------------------------------------------|------ ...